<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563157</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-3.071</org_study_id>
    <nct_id>NCT03563157</nct_id>
  </id_info>
  <brief_title>QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine</brief_title>
  <official_title>NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NantKwest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NantKwest, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: Phase 1b/2 NANT CRC Vaccine vs Regorafenib
      in Subjects with CRC Who have Previously Treated with SOC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NANT Colorectal Cancer (CRC) Vaccine: A phase 1b/2 Trial of the NANT CRC Vaccine vs
      Regorafenib in Subjects with Metastatic CRC Who Have Been Previously Treated with
      Standard-Of-Care Therapy
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 25, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 1b</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival from baseline to progression, per RECIST 1.1</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 2 Randomized Component</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 Single Arm Component</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR for Phase 1b and Phase 2 Randomized Component</measure>
    <time_frame>1 year</time_frame>
    <description>Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS for Phase 1b and Phase 2 Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Progression Free Survival from baseline to progression per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival from first treatment to date of death (any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of Response from date of first response to date of disease progression or death (any cause), per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>1 year</time_frame>
    <description>Disease Control Rate: the number of patients with a CR, PR or SD lasting at least 2 months per RECIST 1.1 and irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of Life as assessed by Patient Reported Outcomes using the FACT-C questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">332</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>mCRC</condition>
  <arm_group>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combination of agents will be administered to subjects in this study: Aldoxorubicin HCI, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In subjects with metastatic CRC who have been previously treated with standard-of-care (SOC) therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldoxorubicin Hydrochloride</intervention_name>
    <description>Aldoxorubicin Hydrochloride HCI</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALT-803</intervention_name>
    <description>Recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1]</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-011</intervention_name>
    <description>Ad5 [E1-, E2b-]-CEA</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-021</intervention_name>
    <description>Ad5 [E1-, E2b-]-[HER2]</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-051</intervention_name>
    <description>Ad5 [E1-, E2b-]-Brachyury</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-061</intervention_name>
    <description>Ad5 [E1-, E2b-]-mucin 1 [MUC1]</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-4000</intervention_name>
    <description>RAS yeast</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6207</intervention_name>
    <description>CEA yeast</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6301</intervention_name>
    <description>Brachyury yeast</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>haNK</intervention_name>
    <description>haNK™, NK-92 [CD16.158V, ER IL-2]</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>BAVENCIO® injection</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>XELODA® tablets</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>ERBITUX® injection</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide Capsules</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-FU; Fluorouracil Injection</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin Calcium</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>ABRAXANE® for Injectable Suspension [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>ELOXATIN® injection</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>STIVARGA® tablets</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
    <arm_group_label>Regorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Stereotactic body radiation therapy</description>
    <arm_group_label>NANT Colorectal Cancer (CRC) Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years.

          2. Able to understand and provide a signed informed consent that fulfills the relevant
             IRB or IEC guidelines.

          3. Histologically-confirmed recurrent or metastatic CRC previously treated with
             fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF
             biological therapy, and if RAS wild-type, an anti-EGFR therapy; or subjects who are
             ineligible for these therapies.

          4. ECOG performance status of 0 or 1.

          5. Have at least 1 measurable lesion of ≥ 1.0 cm.

          6. Must have a recent FFPE tumor biopsy specimen following the conclusion of the most
             recent anticancer treatment and be willing to release the specimen for prospective and
             exploratory tumor molecular profiling. If an historic specimen is not available, the
             subject must be willing to undergo a biopsy during the screening period, if considered
             safe by the Investigator. If safety concerns preclude collection of a biopsy during
             the screening period, a tumor biopsy specimen collected prior to the conclusion of the
             most recent anticancer treatment may be used.

          7. Must be willing to provide blood samples prior to the start of treatment on this study
             for prospective tumor molecular profiling and exploratory analyses.

          8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of
             treatment for exploratory analyses, if considered safe by the Investigator.

          9. Ability to attend required study visits and return for adequate follow-up, as required
             by this protocol.

         10. Agreement to practice effective contraception for female subjects of child-bearing
             potential and non-sterile males. Female subjects of child-bearing potential must agree
             to use effective contraception for up to 1 year after completion of therapy, and non-
             sterile male subjects must agree to use a condom for up to 4 months after treatment.
             Effective contraception includes surgical sterilization (eg, vasectomy, tubal
             ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide,
             IUDs, and abstinence.

             Phase 2 single-arm component only

         11. Must have progressed on or after regorafenib treatment in the randomized phase 2
             portion of the study OR progressed or experienced unacceptable toxicity on SoC and
             regorafenib prior to enrollment on the study.

        Exclusion Criteria:

          1. MSI-high or MMR-deficient tumors eligible for, but not yet treated with, a PD-1
             inhibitor.

          2. Serious uncontrolled concomitant disease that would contraindicate the use of the
             investigational drugs used in this study or that would put the subject at high risk
             for treatment-related complications.

          3. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's
             disease, or autoimmune disease associated with lymphoma).

          4. History of organ transplant requiring immunosuppression.

          5. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative
             colitis).

          6. Inadequate organ function, evidenced by the following laboratory results:

               1. ANC &lt; 1,000 cells/mm^3.

               2. Uncorrectable grade 3 anemia (hemoglobin &lt; 8 g/dL)

               3. Platelet count &lt; 75,000 cells/mm^3.

               4. Total bilirubin &gt; ULN (unless the subject has documented Gilbert's syndrome).

               5. AST (SGOT) or ALT (SGPT) &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver
                  metastases).

               6. ALP &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver metastases, or &gt;10 × ULN in
                  subjects with bone metastases).

               7. Serum creatinine &gt; 2.0 mg/dL or 177 μmol/L.

               8. Serum anion gap &gt; 16 mEq/L or arterial blood with pH &lt; 7.3.

          7. Uncontrolled hypertension (systolic &gt; 160 mm Hg and/or diastolic &gt; 110 mm Hg) or
             clinically significant (ie, active) cardiovascular disease, cerebrovascular
             accident/stroke, or myocardial infarction within 6 months prior to first study
             medication; unstable angina; congestive heart failure of New York Heart Association
             grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with
             uncontrolled hypertension should be medically managed on a stable regimen to control
             hypertension prior to study entry.

          8. Serious myocardial dysfunction defined by ECHO as absolute LVEF 10% below the
             institution's lower limit of predicted normal.

          9. Dyspnea at rest due to complications of advanced malignancy or other disease requiring
             continuous oxygen therapy.

         10. Positive results of screening test for HIV.

         11. Current chronic daily treatment (continuous for &gt; 3 months) with systemic
             corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone),
             excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic
             reaction or anaphylaxis in subjects who have known contrast allergies is allowed.

         12. Known hypersensitivity to any component of the study medication(s).

         13. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug
             reaction with any of the study medications.

         14. Concurrent or prior use of a strong CYP3A4 inhibitor (including ketoconazole,
             itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir,
             ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong
             CYP3A4 inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin,
             phenobarbital, and St John's Wort) within 14 days before study day 1.

         15. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8
             inducer (rifampin) within 14 days before study day 1.

         16. Participation in an investigational drug study or history of receiving any
             investigational treatment within 30 days prior to screening for this study, except for
             testosterone-lowering therapy in men with prostate cancer.

         17. Assessed by the Investigator to be unable or unwilling to comply with the requirements
             of the protocol.

         18. Concurrent participation in any interventional clinical trial.

         19. Pregnant and nursing women.

             Phase 2 randomized component only

         20. Prior regorafenib treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

